Tatva Chintan Pharma logo

Tatva Chintan Pharma

TATVA NSE

Key Fundamentals

MicrocapSpecialty ChemicalsChemicals
Market Cap
₹3,791 Cr
Volatility
Moderate
P/E Ratio
73.22
EBITDA
₹96.70 Cr
Return on Equity
5.38%
Debt to Equity
0.15
Book Value
₹334.2
EPS
₹11.14
52W High
₹1,838.1
52W Low
₹981.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 22.5%
  • Company's working capital requirements have reduced from 133 days to 92.0 days

Weaknesses

4
  • Stock is trading at 4.81 times its book value
  • The company has delivered a poor sales growth of 11.0% over past five years.
  • Company has a low return on equity of 3.68% over last 3 years.
  • Promoter holding has decreased over last 3 years: -7.15%

Growth Rate

Revenue Growth
32.31% higher than 3Y
Net Income Growth
639% higher than 3Y
Cash Flow Change
27.13% higher than 3Y
ROE
599% higher than 3Y
ROCE
531% higher than 3Y
EBITDA Margin (Avg.)
100% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Tatva Chintan Pharma Chem trades at a market cap of ₹2,974 Cr with a PE of 69.4x and P/B of 3.74x. The company reported FY25 revenue of ₹505.86 Cr (up ~32% YoY from ₹382.71 Cr in FY24) with net profit recovering to ₹42.05 Cr from a trough of ₹5.71 Cr in FY24, though profitability remains well below its FY22 peak of ₹95.87 Cr net profit.

Bull Case 7
  • TTM revenue growth of 32% signals a strong recovery, with FY25 sales at ₹505.86 Cr vs ₹382.71 Cr in FY24
  • Net profit surged from ₹5.71 Cr in FY24 to ₹42.05 Cr in FY25, a ~636% increase indicating a cyclical earnings turnaround
  • Working capital efficiency improved significantly from 133 days to 92 days, freeing up cash flow
  • Operating profit recovered to ₹89.33 Cr in FY25 from ₹25.84 Cr in FY24, indicating margin restoration
  • Company maintains a consistent dividend payout averaging 22.5%, demonstrating shareholder return discipline
  • Stock has delivered 24% returns over the past 1 year, outperforming amid the earnings recovery
  • EPS recovered to ₹17.98 in FY25 from ₹2.44 in FY24, validating the profit turnaround trajectory
Bear Case 8
  • PE ratio of 69.4x is elevated, pricing in significant future growth that may not materialize
  • 3-year ROE averages just 4% and last year ROE is only 6%, well below cost of equity for a specialty chemicals company
  • 5-year compounded sales growth of only 11% and 5-year profit CAGR of -4% indicate a structurally weak growth record
  • Promoter holding has declined by 7.15% over last 3 years, signaling reduced insider confidence
  • FY25 net profit of ₹42.05 Cr remains 56% below the FY22 peak of ₹95.87 Cr, suggesting full recovery is still distant
  • P/B ratio of 3.74x is expensive given the low single-digit ROE profile
  • 3-year stock CAGR of -11% reflects sustained value destruction for medium-term holders
  • Dividend yield of just 0.08% offers negligible income support at current valuation

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Neutral 2
  • Trading window closed for Q1FY27 Jun 23

    Tatva Chintan closed its trading window from July 1, 2026, until 48 hours after Q1FY27 results are declared, a routine compliance measure.

  • Investor meet with Valcore Capital Jun 12

    Tatva Chintan will hold a virtual one-on-one meeting with Valcore Capital Advisors on June 17, 2026. No unpublished price sensitive information will be shared.

TL;DR: Recent news flow for Tatva Chintan is limited to routine corporate governance disclosures with no material positive or negative catalysts. The trading window closure signals Q1FY27 results are approaching, which will be the next meaningful data point. No operational or sector-specific headwinds have surfaced in the latest updates. Investors should watch for Q1FY27 earnings for direction on revenue trends and margin trajectory.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
114
97
84
98
105
83
86
108
117
124
131
134
167
Expenses
93
76
73
83
93
78
79
99
100
101
106
106
135
Operating Profit
21
20
11
16
13
6
7
9
17
22
25
28
32
OPM %
19%
21%
13%
16%
12%
7%
8%
8%
15%
18%
19%
21%
19%
Other Income
1
1
1
5
1
0
0
1
1
1
2
0
1
Interest
3
3
0
0
0
0
0
0
0
1
0
1
2
Depreciation
6
7
7
6
7
7
7
7
9
9
9
10
11
PBT
13
11
5
14
7
-1
0
2
9
14
18
17
21
Tax %
29%
31%
34%
30%
24%
-34%
-165%
49%
27%
27%
14%
38%
24%
Net Profit
10
8
3
10
5
-1
0
1
7
10
15
10
16
EPS in Rs
4.29
3.33
1.48
4.11
2.23
-0.28
0.06
0.44
2.84
4.24
6.49
4.41
6.83
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
136
206
263
300
434
424
394
383
506
556
Expenses
113
172
208
234
325
363
325
348
412
448
Operating Profit
23
34
55
67
109
61
69
35
94
108
OPM %
17%
17%
21%
22%
25%
14%
17%
9%
18%
19%
Other Income
1
1
1
5
9
2
7
2
3
4
Interest
3
4
4
4
5
9
7
2
3
5
Depreciation
3
4
5
7
8
10
26
28
37
38
PBT
19
27
48
61
104
45
44
8
57
69
Tax %
35%
25%
21%
14%
8%
-2%
30%
25%
26%
—
Net Profit
12
21
38
52
96
45
30
6
42
51
EPS in Rs
15.3
25.56
47.03
26.02
43.25
20.52
12.97
2.44
17.98
21.97
Div. Payout %
0%
0%
0%
19%
5%
10%
15%
41%
11%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
20
22
22
23
23
23
Reserves
51
72
110
146
451
493
714
715
758
Borrowings
56
77
91
90
120
170
14
36
120
Other Liabilities
28
31
41
59
65
74
67
61
102
Total Liabilities
144
188
249
315
658
759
819
836
1,004
Fixed Assets
57
67
111
120
160
196
427
529
609
CWIP
10
6
5
10
51
231
77
24
25
Investments
1
0
0
0
0
0
10
0
4
Other Assets
76
115
133
185
447
332
305
283
365
Total Assets
144
188
249
315
658
759
819
836
1,004
Figures in ₹ Crores

Cash Flow

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
7
25
20
20
28
98
25
31
Investing
-30
-17
-40
-21
-197
-101
-121
-65
-116
Financing
7
17
10
-5
235
38
31
17
79
Net Cash Flow
-10
8
-5
-6
59
-36
8
-24
-6
Free Cash Flow
-18
-2
-23
-1
-69
-175
-30
-51
-82
CFO/OP
105
39
61
44
36
61
157
85
42
Figures in ₹ Crores

Ratios

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
77
73
69
110
48
73
65
85
86
Inventory Days
148
114
175
173
319
262
320
246
319
Days Payable
127
71
87
114
83
52
94
60
95
Cash Conversion Cycle
99
116
157
169
283
283
291
271
310
Working Capital Days
15
46
47
74
74
25
158
148
92
ROCE %
—
22%
28%
28%
26%
9%
7%
1%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Tatva Chintan Pharma insights

47 extracted metrics + investor summaries across FY18–FY27.

Log in — free

Shareholding Pattern

DIIs3.11%Promot.72.02%Others3.45%FIIs3.93%Public17.48%As ofJun 2026

Documents

Frequently Asked Questions about Tatva Chintan Pharma

What does Tatva Chintan Pharma Chem Ltd do?
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
Where is Tatva Chintan Pharma Chem Ltd (TATVA) listed?
Tatva Chintan Pharma Chem Ltd trades as TATVA on the NSE and under code 543321 on the BSE.
Which sector does Tatva Chintan Pharma Chem Ltd belong to?
Tatva Chintan Pharma Chem Ltd is classified under the Commodities sector, in the Chemicals & Petrochemicals industry.
What is the market capitalisation of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd has a market capitalisation of ₹3,791 Cr, which places it in the Small Cap band.
What is the PE ratio of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd trades at a PE ratio of 73.22, on earnings per share of ₹11.14, against a book value of ₹334.2 per share.
What is the 52-week high and low of Tatva Chintan Pharma Chem Ltd?
Over the last 52 weeks Tatva Chintan Pharma Chem Ltd has traded between ₹981.5 and ₹1,838.1.
Does Tatva Chintan Pharma Chem Ltd pay dividends?
Tatva Chintan Pharma Chem Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd reported a return on equity of 5.38%. Its debt-to-equity ratio is 0.15.

Company Information

Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]

Website tatvachintan.com
Listed 2021-07-29
Face Value ₹ 10
Issued Size 2,33,92,055

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TATVA.md for Tatva Chintan Pharma Chem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Commodities → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List